Document Detail


CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept.
MedLine Citation:
PMID:  17916208     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Tumour necrosis factor-alpha upregulates the expression of a cutaneous T cell-attracting chemokine (CTACK/CCL27), that promotes migration of cutaneous lymphocyte-associated antigen-positive lymphocytes into the skin. The role of CTACK/CCL27 in pathogenesis of psoriasis has recently been documented but no data are available at the present time on its modification in psoriatic cutaneous tissue after administration of etanercept. OBJECTIVES: To evaluate modifications of CTACK/CCL27 expression in skin of patients with psoriasis after administration of etanercept and their relation with disease activity. METHODS: Twenty-two patients with moderate to severe psoriasis underwent clinical, histological and immunohistochemical evaluations of disease activity at baseline and at 12 and 24 weeks after starting treatment with etanercept. RESULTS: All selected patients experienced an improvement of Psoriasis Area and Severity Index (PASI) score (P < 0.001) and Dermatology Life Quality Index score (P < 0.001) during the treatment. Skin histological abnormalities showed statistically significant modifications during treatment (P < 0.001). Immunohistochemical expression of CTACK/CCL27 decreased significantly (P < 0.001) and its relation with final PASI score was statistically significant (P < 0.05); the pattern of distribution of CTACK/CCL27 immunoreactivity significantly moved from diffuse and predominantly suprabasal to basal (P < 0.001) and the restoration of basal distribution of CTACK/CCL27 was also significantly related to clinical improvement of cutaneous disease (P < 0.001). CONCLUSIONS: Etanercept induces a clinical and histological improvement of psoriatic disease, promoting a reduction in CTACK/CCL27 cutaneous immunostaining and favouring the restoration of physiological CTACK/CCL27 epidermal expression. Moreover, CTACK/CCL27 reduction in cutaneous expression during administration of etanercept could be considered a favourable prognostic marker.
Authors:
A Campanati; G Goteri; O Simonetti; G Ganzetti; K Giuliodori; D Stramazzotti; D Morichetti; M L Bernardini; B Mannello; G Fabris; A Offidani
Related Documents :
11716328 - Peripartum cardiomyopathy: clinical and therapeutic aspects.
16863558 - Does pregnancy change the disease course? a study in a european cohort of patients with...
18818938 - Pregnancy in chronic renal insufficiency: single centre experience from north india.
10486498 - The evolution of linitis plastica as a consequence of advanced gastric carcinoma in pre...
19287178 - Effect of second pregnancy on maternal carriage and outcome of high-risk human papillom...
3141958 - Alcohol-related birth defects: an update.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2007-10-04
Journal Detail:
Title:  The British journal of dermatology     Volume:  157     ISSN:  0007-0963     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-11-20     Completed Date:  2008-04-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1155-60     Citation Subset:  IM    
Affiliation:
Dermatological Clinic, Department of Medical Sciences, Ancona Hospital, Polytechnic University of Marche Region, Via Conca 71, Ancona, Italy. a.campanati@ao-umbertoprimo.marche.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Chemokine CCL27 / metabolism*
Female
Humans
Immunoglobulin G / therapeutic use*
Immunohistochemistry
Male
Psoriasis / drug therapy*,  metabolism*
Receptors, Chemokine
Receptors, Tumor Necrosis Factor / therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/CCL27 protein, human; 0/Chemokine CCL27; 0/Immunoglobulin G; 0/Receptors, Chemokine; 0/Receptors, Tumor Necrosis Factor; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks.
Next Document:  Potassium channel openers accelerate epidermal barrier recovery.